open access

Vol 27, No 4 (2021)
Review paper
Published online: 2022-01-28
Get Citation

Thromboprophylaxis in patients with Covid-19

DOI: 10.5603/AA.2021.0016
·
Acta Angiologica 2021;27(4):138-143.
Affiliations
  1. National Tuberculosis and Lung Diseases Research Institute Warsaw Poland, Plocka 26, 01-138 Warsaw, Poland
  2. Masovian Cancer Hospital, Wieliszew, Poland, Kościelna 61, 05-135 Wieliszew, Poland

open access

Vol 27, No 4 (2021)
-- For assignment --
Published online: 2022-01-28

Abstract

Abstract For two years, the entire world has been grappling with the new challenge that is the Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to Covid-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomised trials.

Abstract

Abstract For two years, the entire world has been grappling with the new challenge that is the Covid-19 pandemic. In December 2019 in China’s largest province, Wuhan, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), was detected in a patient with severe respiratory failure. Shortly after, infections were detected in all regions of the world. So far, 265 million infections have been confirmed around the world, and 5.2 million of those infected have died due to Covid-19. Infection with SARS-CoV-2 is associated with an increased risk of cardiovascular complications, especially thromboembolic complications. Low-molecular-weight-heparin presents a basic form of prophylaxis against thromboembolic complications in individuals who are ill with COVID-19. Controversy still exists regarding the optimal dose of LMWH depending on disease severity, this problem requires further randomised trials.

Get Citation

Keywords

thromboprophylaxis, Covid-19 thrombosis

About this article
Title

Thromboprophylaxis in patients with Covid-19

Journal

Acta Angiologica

Issue

Vol 27, No 4 (2021)

Article type

Review paper

Pages

138-143

Published online

2022-01-28

Page views

1095

Article views/downloads

117

DOI

10.5603/AA.2021.0016

Bibliographic record

Acta Angiologica 2021;27(4):138-143.

Keywords

thromboprophylaxis
Covid-19 thrombosis

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl